Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), just announced a positive, top-line result in a Phase 2 clinical trial of their experimental therapy LX4211 in type 1 diabetes. LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2, was designed to lower blood glucose levels through two insulin-independent mechanisms of action. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock performance was 5.16% in last session and finished the day at $1.63. Traded volume was 1.41million shares in the last session and the average volume of the stock remained 1.35million shares. The beta of the stock remained 2.03. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) insider ownership is 0.30%.

Corcept Therapeutics, Inc. (NASDAQ:CORT) entered into a manufacturing agreement (the “Agreement”) with AAIPharma Services Corp. (“AAI”), pursuant to which AAI will manufacture and package Korlym tablets (the “product”). We will supply mifepristone, the active pharmaceutical ingredient in Korlym, to AAI for use in the manufacture of the product. AAI will manufacture the product in accordance with FDA and other regulatory requirements. Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 5.80 percent to $3.83 Thursday on volume of 421,704.00million shares. The intra-day range of the stock was $3.55 to $3.87. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $385.64million.

Biotechnology is thriving this week with 71% of stocks in the sector (60 out of 84) currently rating a “buy”. Gentium S.p.A. Sponsored ADR (GENT), Repligen Corporation (RGEN) and Insys Therapeutics, Inc. (NASDAQ:INSY) are paving the way for the sector with A grades. Insys Therapeutics Inc (NASDAQ:INSY)’s stock on Apr 17, 2014 reported a increase of 5.11% to the closing price of $38.64. Its fifty two weeks range is $5.56 -$67.70. The total market capitalization recorded $1.32billion. The overall volume in the last trading session was 299,694.00million shares. In its share capital, INSY has 33.41million outstanding shares.

Emerging pharmaceutical company, ANI Pharmaceuticals Inc. (NASDAQ:ANIP), recently announced the extension of a fee for service product development agreement with Sterling Pharmaceutical Services. The generic drug product that will form basis of the agreement has not yet been disclosed. On Thursday, shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) advanced 3.07% to close the day at $25.55. Company return on investment (ROI) is 2.20% and its monthly performance is recorded as -21.48%. ANI Pharmaceuticals Inc (NASDAQ:ANIP) quarterly revenue growth is 9.80%.